1. Adams S. Roche versus Adams. London: J. Cape; 1984.

2. Kesselheim A.S., Studdert D.M., Mello M.M. Whistle-blowers’ experiences in fraud litigation against pharmaceutical companies. N Engl J Med. 2010; 362: 1832–9.

3. Rost P. The Whistleblower: confessions of a healthcare hitman. New York: Soft Skull Press; 2006.

4. Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.

5. Drug Industry Document Archive. University of California, San Francisco. Available online at: http://dida.library.ucsf.edu/search?query=argumentative (accessed 21 September 2012).

6. Day M. Don’t blame it all on the bogey. BMJ. 2007; 334: 1250–1.

7. Shuchman M. Drug company threatens legal action over Canadian guidelines. BMJ. 1999; 319: 1388.

8. Tougaard H., Hundevadt K. [The golden promises of the gynaecologists]. Jyllandsposten. 2004 Jan 18.

9. Villesen K. [The drug companies earn fortunes while raising doubt]. Information. 2011 Dec 9.

10. Glaxo ‘downplayed’ warning on heart-attack risk from AIDS drug. The Independent. 2008 May 12.

11. Brix S.M. [Researcher receives death threats]. Universitetsavisen. 2008; 14: 5.

12. Perner A., Haase N., Guttormsen A.B., et al. Hydroxyethyl Starch 130/042. versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012; 367: 124–34.

13. Klawitter U., Stief M. Demand for correction of article entitled ‘Hydroxyethyl Starch 130/04. versus Ringer’s Acetate in Severe Sepsis’ (published online on June 27, 2012). Letter. 2012 July 9.

14. Corrections. N Engl J Med. 2012; 367: 481.

15. Kupferschmidt K. Squabble Over NEJM paper puts spotlight on antishock drug. ScienceInsider. 2012 Aug 2.

16. Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.

17. Brynner R., Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.

18. Kassirer J.P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.

19. Fries J.F. Letter to Raymond Gilmartin re: physician intimidation. 9 Jan, 2001. Merck. Bates No MRK-ABH0002204 to MRK-ABH0002207. Available online at: www.vioxxdocuments.com/Documents/Krumholz_Vioxx/Fries2001.pdf (accessed 10 October 2007).

20. Wood S. Eric Topol loses provost/chief academic offi cer titles at Cleveland Clinic and Lerner College. Heartwire. 2005 Dec 12.

21. Rout M. Vioxx maker Merck and Co drew up doctor hit list. The Australian. 2009 April 1.

22. Blowing the whistle on the FDA: an interview with David Graham. Multinational Monitor. 2004; 25(12).

23. Lenzer J. Crisis deepens at the US Food and Drug Administration. BMJ. 2004; 329: 1308.

24. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet. 2005; 365: 475–81.

25. Lenzer J. Public interest group accuses FDA of trying to discredit whistleblower. BMJ. 2004; 329: 1255.

26. Lenzer J. US government agency to investigate FDA over rofecoxib. BMJ. 2004; 329: 935.

27. Lenzer J. FDA bars own expert from evaluating risks of painkillers. BMJ. 2004; 329: 1203.

28. Lenzer J. Pfi zer criticised over delay in admitting drug’s problems. BMJ. 2004; 329: 935.

29. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 2004; 364: 1995–6.

30. Eaton L. Editor claims drug companies have a ‘parasitic’ relationship with journals. BMJ. 2005; 330; 9.

31. Andersen N.V., Drachmann H. [Pharmaceutical giant blacklisted]. Politiken. 2004 Mar 25.

32. [Verdict in the Press Council in case 2004-6-45]. Pressenævnet. 2004 Aug 18.

33. Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.

34. Mello M.M., Clarridge B.R., Studdert D.M. Academic medical centers’ standards for clinical-trial agreements with industry. N Engl J Med. 2005; 352: 2202–10.

35. Williams H.C. Evening primrose oil for atopic dermatitis. BMJ. 2003; 327: 1358–9.

36. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefi eld; 2008.

37. Boseley S. Bitter pill. The Guardian. 2001 May 7.

38. Schafer A. Biomedical conflicts of interest: a defence of the sequestration thesis – learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004; 30: 8–24.

39. Healy D. Let Them Eat Prozac. New York: New York University Press; 2004.

40. Healy D. Medical partisans? Why doctors need confl icting interests. Aust N Z J Psychiatry. 2012; 46: 704–7.

41. Baylis F. The Olivieri debacle: where were the heroes of bioethics? J Med Ethics. 2004; 30: 44–9.

42. Dyer C. Aubrey Blumsohn, academic who took on industry. BMJ. 2010; 340: 22–3.

43. Revill J. Doctor accuses drug giant of ‘unethical’ secrecy. Observer. 2005 Dec 4.

44. Revill J. How the drugs giant and a lone academic went to war. Observer. 2005 Dec 4.

45. Dyer C. Professor to face GMC over his claim to have seen full trial data. BMJ. 2009; 339: 774–5.

46. Gornall J. A very public break-up. BMJ. 2010; 340: 180–3.

47. Wilmshurst P. The effects of the libel laws on science – a personal experience. Radical Statistics. 2011: 104: 13–23.

48. Wikipedia. Simon Singh. Available online at: http://en.wikipedia.org/wiki/Simon_Singh (accessed 17 June 2010).

49. Singh S. This is goodbye. The Guardian. 2010 March 12.

50. Dyer C. Charity sets up fund to defend researcher being sued for libel. BMJ. 2008; 337: 1313.

51. Tanne J.H. FDA places ‘black box’ warning on antidiabetes drugs. BMJ. 2007; 334: 1237.

52. Burton B. Diabetes expert accuses drug company of ‘intimidation’. BMJ. 2007; 335: 1113.

53. Cohen D. Drug study secrecy puts lives at risk. Index on Censorship. 2011 Nov 29.

54. DeAngelis C.D., Fontanarosa P.B. Ensuring integrity in industry-sponsored research. JAMA. 2010; 303: 1196–8.

55. Lenzer J., Brownlee S. Reckless medicine. Discover. 2010; 11: 64–76.

56. Gøtzsche P.C., Hróbjartsson A., Johansen H.K., et al. Constraints on publication rights in industryinitiated clinical trials. JAMA. 2006; 295: 1645–6.

57. Gøtzsche P.C., Hróbjartsson A., Johansen H.K., et al. [Constraints on publication rights in industry-initiated clinical trials: secondary publication]. Ugeskr Læger. 2006; 168: 2467–9.

58. Gornall J. Research transparency: industry attack on academics. BMJ. 2009; 338: 626–8.